| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 67028 |
Intravitreal injection of a pharmacologic agent |
39,405 |
28,482 |
$2.39M |
| J0178 |
Injection, aflibercept, 1 mg |
2,488 |
1,477 |
$1.22M |
| 92014 |
Ophthalmological services: medical examination and evaluation, comprehensive, established patient |
32,561 |
24,928 |
$721K |
| J9035 |
Injection, bevacizumab, 10 mg |
29,522 |
16,934 |
$608K |
| 92134 |
|
49,209 |
36,600 |
$493K |
| Q5128 |
Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg |
1,290 |
720 |
$221K |
| 92250 |
|
8,784 |
7,186 |
$188K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
2,062 |
1,694 |
$109K |
| Q5124 |
Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg |
43 |
13 |
$6K |
| 99223 |
Prolong inpt eval add15 m |
43 |
38 |
$5K |
| 99233 |
Prolong inpt eval add15 m |
38 |
26 |
$3K |
| 92235 |
|
78 |
60 |
$3K |
| J3590 |
Unclassified biologics |
365 |
190 |
$2K |
| J7999 |
Compounded drug, not otherwise classified |
25 |
12 |
$87.83 |